Noninvasive electrical stimulation of the brain for 20 minutes per session over four days has been demonstrated to improve both working- and long-term memory for at least one month, in people ages 65 to 88.
Scientists have discovered an RNA-based mechanism that is involved in core hallmarks of a number of accelerated aging conditions and shown that therapies targeting this RNA reverses some of these hallmarks in human cells and extend life spans in mouse models.
A new method has been devised to produce generic chimeric antigen receptor (CAR) T cells at scale by directing induced pluripotent stem cells to differentiate into mature T cells in vitro. The generic T cells can then be engineered to express a range of different chimeric antigen receptors.
Researchers are closer to better diagnosing and treating age-related macular degeneration (AMD) after discovering new genetic signatures of the disease by reprogramming stem cells to generate high-resolution disease models.
Sequence analysis of 131 human brains has revealed the mutagenesis processes that take place throughout life, from development to senescence. In a new study published in the July 29, 2022, issue of Science, the authors described how high rates of brain somatic mutations (what they call hypermutability) correlated with age.
It is now possible to look up the 3D structure of every known protein following the latest release of Alphafold, an open database run in partnership by Deepmind, the London-based artificial intelligence company owned by Google parent Alphabet and the European Molecular Biology Laboratory’s European Bioinformatics Institute in Cambridge, U.K.
Scientists will investigate whether cutting-edge technology such as base editing could be used to cure inherited heart muscle conditions after an international team co-led by Harvard Medical School won a research challenge. The $36 million Big Beat Challenge, run by the British Heart Foundation, is one of the largest non-commercial awards ever given and will focus on inherited heart muscle diseases known as genetic cardiomyopathies.
Since the very beginning of the COVID-19 pandemic, in addition to the attempts to rapidly develop a vaccine that was effective against current strains, researchers have been looking for a vaccine that could protect more broadly against multiple coronaviruses. That has prompted attempts to harness the potential of the more conserved S2 subunit of the spike protein via which SARS-CoV-2 enters human host cells.
The controversy about the origins of the SARS-CoV-2 virus and the accusations that it escaped from the Wuhan Institute of Virology, or even that it was deliberately engineered there, could – possibly – be brought to a close by two papers published July 26, 2022.
Since the isolation of SARS-CoV-2 and the study of its infection mechanisms, scientists have been trying to understand how this virus accesses the brain and produces neurological symptoms. The receptor necessary for the virus to enter the cell by endocytosis (the receptor for angiotensin-converting enzyme 2, ACE2) is only expressed by some neurons and is hardly detected in the brain.